Kenvue Inc

Investor update: Kenvue’s January 29 merger vote, $0.2075 quarterly dividend, and over 90k institutional shares sold—what this means for shareholders.

Institutional sell‑offs hit Kenvue, yet a new partnership with Kimberly‑Clark México could offset the dip—discover how the move may reshape its growth prospects.

Discover why investors are watching Kenvue’s upcoming earnings—key revenue, margin and dividend insights that could shape its 2026 outlook.

How Kenvue’s Tylenol‑autism lawsuit threatens its stock and strategy – read the latest risk analysis.

Explore Kenvue Inc.’s 2025 stock performance, valuation metrics and growth strategy, and discover why investors watch its consumer health dynamics.

How Kenvue’s stock surged on Nov 23 amid takeover whispers – explore the market reaction, key analysts’ insights, and what this could mean for investors.

Kenvue Inc. reports a decline in Q2 2025 sales, prompting a revised full-year outlook and a lower target price from analysts.

Kenvue Inc. is undergoing a leadership transition and strategic review, with a new interim CEO and plans to off-load smaller beauty brands, sparking a positive market reaction.

Kenvue Inc. has announced a leadership transition, appointing Kirk Perry as interim CEO, amid a strategic review prompted by a decline in sales and a need to reposition the company in the competitive consumer staples sector.

Kenvue Inc. is making significant strides in sustainability while maintaining a strong market position, positioning itself as a forward-thinking leader in the consumer health industry.